WO2021099901A1 - Stable topical pharmaceutical composition - Google Patents

Stable topical pharmaceutical composition Download PDF

Info

Publication number
WO2021099901A1
WO2021099901A1 PCT/IB2020/060687 IB2020060687W WO2021099901A1 WO 2021099901 A1 WO2021099901 A1 WO 2021099901A1 IB 2020060687 W IB2020060687 W IB 2020060687W WO 2021099901 A1 WO2021099901 A1 WO 2021099901A1
Authority
WO
WIPO (PCT)
Prior art keywords
calcipotriol
fluorouracil
pharmaceutical composition
composition
topical pharmaceutical
Prior art date
Application number
PCT/IB2020/060687
Other languages
French (fr)
Inventor
Vinay Kumar SINGH
Aditya M Patel
Alex K George
Original Assignee
Intas Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd. filed Critical Intas Pharmaceuticals Ltd.
Publication of WO2021099901A1 publication Critical patent/WO2021099901A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • the present invention provides a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, for use in the treatment of actinic keratosis and other skin diseases. Further, the present invention provides a process for the preparation of the said composition. BACKGROUND OF THE INVENTION
  • 5-Fluorouracil is thymidylate synthase (TS) inhibitor, which is chemically 5- Fluoro-IH, 3H-pyrimidine-2,4-dione.
  • TS thymidylate synthase
  • the empirical formula of 5-Fluorouracil is C 4 H 3 FN 2 O 2 and it has the structural formula (I).
  • 5-Fluorouracil is sold under the brand name as Adrucil ® Injection and Efudex ® Cream.
  • Adrucil ® Injection By injection into a vein, it is used for colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer.
  • As a cream it is used for actinic keratosis, basal cell carcinoma, and skin warts.
  • Efudex ® Cream is stored at 25° C; excursions permitted to 15°C to 30°C.
  • Calcipotriol also known as calcipotriene, is a synthetic derivative of calcitriol, a form of vitamin D, which is chemically (lR,3S,5E)-5- ⁇ 2-[(lR,3aS,4Z,7aR)-l- [(2R,3E)5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7amethyl-octahydro-lH-inden- 4-ylidene]ethylidene ⁇ -4-methylidenecyclohyytyexane-l,3-diol.
  • the empirical formula of Calcipotriol is C27H40O3 and it has the structural formula (II).
  • Calcipotriol is sold under the trade name Dovonex ® in the United States, Daivonex ® outside North America, and Psorcutan ® in Germany. It is used in the treatment of psoriasis. It is safe for long-term application in psoriatic skin conditions. Dovonex ® is stored at controlled room temperature 15° C to 25° C.
  • US Patent No. US7169401 discloses a skin hydrating cream base consisting essentially of a hypoallergenic peanut oil, and an active ingredient, wherein said the active ingredient is fluorouracil.
  • the US Patent No. US6670335 discloses an oil-in-water emulsion formulation containing fluorouracil suitable for topical administration, and is useful for the treatment of solar keratosis, actinic keratosis, and superficial basal cell carcinoma.
  • the PCT Patent application No. WO2016040638 discloses compositions and methods for the treatment of precancerous skin lesions.
  • the compositions of the invention comprise 5-fluorouracil (5-FU) and a vitamin D analog.
  • 5-FU 5-fluorouracil
  • calcipotriol results in significantly higher clearance of actinic keratosis as compared to standard of care treatment (5-FU+Vaseline).
  • standard of care treatment (5-FU+Vaseline).
  • the patent specification does not provide any reference related to a stable composition comprising 5-FU and calcipotriol.
  • the combination therapy has proved to be a preferred solution to improve patient’s adherence when a treatment requires the co-administration of drugs. Additionally, the combination therapy can reduce the costs of production and distribution of the treatment. However, in many cases, the design of a combination proves difficult for the reason such as chemical incompatibility between the different active ingredients or difficulties for co-formulating active ingredients to be administered with different release.
  • the inventors of the present invention have developed a new stable fixed-dose topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, for use in the treatment of actinic keratosis and other skin diseases.
  • the main object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof.
  • Another object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream, an ointment, or a lotion.
  • Another object of the present invention is to provide a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is more than 7.
  • Another object of the present invention is to provide a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is from 7 to 9.
  • Another object of the present invention is to provide a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is from 7 to 9 and further comprising a chelating agent.
  • Another object of the present invention is to provide a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient selected from an emollient, an emulsifying agent, an ointment base, a chelating agent, a preservative, an antioxidant, a buffering agent, a humectant, a penetration enhancer and a solvent.
  • Another object of the present invention is to provide a process for preparation of stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream, an ointment, or a lotion.
  • Another object of the present invention is to provide a process for preparation of stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream prepared by mixing the components of the water phase and the wax phase.
  • Another object of the present invention is to provide a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the individual assay of 5- Fluorouracil and Calcipotriol in the said composition is at least 95% when stored at 25 °C / 60% RH for at least one month.
  • Another object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the total impurity in the said composition is not more than 5% when stored at 25 °C / 60% RH for at least one month.
  • Another object of the present invention refers to an aluminum collapsible tube packaging container comprising a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof.
  • Another object of the present invention is to provide a stable topical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, for human administration for the treatment of actinic keratosis, precancerous skin lesions and other skin diseases.
  • the present invention relates to a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof.
  • the present invention relates to a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream, an ointment, or a lotion.
  • the present invention relates to a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof with at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is more than 7.
  • the present invention relates to a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is from 7 to 9.
  • the present invention relates to a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is from 7 to 9 and further comprising a chelating agent.
  • the present invention relates to a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients selected from an emollient, an emulsifying agent, an ointment base, chelating agent, preservative, antioxidant, buffering agent, humectant, penetration enhancer and solvent.
  • the present invention relates to a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and the following pharmaceutically acceptable excipients: cetostearyl alcohol, petrolatum, liquid paraffin, dichlorobenzyl alcohol, dl-a tocopherol, ceteth-20 ® , disodium hydrogen phosphate dihydrate, disodium edetate, glycerin, and sodium hydroxide and purified water.
  • cetostearyl alcohol petrolatum, liquid paraffin, dichlorobenzyl alcohol, dl-a tocopherol, ceteth-20 ® , disodium hydrogen phosphate dihydrate, disodium edetate, glycerin, and sodium hydroxide and purified water.
  • the present invention relates to a process for preparation of stable topical pharmaceutical composition
  • a process for preparation of stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream prepared by mixing the components of the water phase and the wax phase.
  • the present invention relates to a stable topical pharmaceutical composition
  • a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the individual assay of 5- Fluorouracil and Calcipotriol in the said composition is at least 95% when stored at 25 °C / 60% RH for at least one month.
  • the present invention relates to a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the total impurity in the said composition is not more than 5% when stored at 25 °C / 60% RH for at least one month.
  • the present invention relates to a stable topical composition comprising 2.5% w/w of 5-Fluorouracil and 0.0025% w/w of Calcipotriol or pharmaceutically acceptable salts thereof, wherein the pH of the said composition is from 7 to 9, and total impurity in the said composition is not more than 5% when stored at 25 °C / 60% RH for at least one month.
  • the present invention relates to a stable topical composition
  • a stable topical composition comprising 5% w/w of 5-Fluorouracil and 0.0050% w/w of Calcipotriol or pharmaceutically acceptable salts thereof, wherein the pH of the said composition is from 7 to 9, and total impurity in the said composition is not more than 5% when stored at 25 °C / 60% RH for at least one month.
  • the present invention relates to a stable topical composition
  • a stable topical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition can be used for human administration for the treatment of actinic keratosis, precancerous skin lesions and other skin diseases.
  • the present invention provides a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream, an ointment, or a lotion.
  • stable pharmaceutical composition of the present invention means the topical composition retains consistency as a white opaque cream and the individual assay of 5-Fluorouracil and Calcipotriol in the said composition is at least 95% when stored at 25 °C / 60% RH for at least one month, preferably for at least 2 months, and more preferably for at least 3 months.
  • RH stands for relative humidity corresponding to the storage conditions.
  • the individual assay of the active ingredient can be carried out by any conventional analytical methods, preferably by HPLC method.
  • HPLC High-performance liquid chromatography
  • the HPLC method is well known in the art for the quantification and qualification of analytes.
  • Impurity B (5Z,7Z,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22- tetraene- 1 a,3b,244c ⁇ o1 ((7Z)-calcipotriol),
  • Impurity C (5E,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22- tetraene- 1 a,3b,244c ⁇ o1 ((5E)-calcipotriol),
  • Impurity D (5Z,7E,22E,24R)-24-cyclopropyl-9,10-secochola-5,7,10(19),22- tetraene- 1 a,3b,244c ⁇ o1 (24-epi-calcipotriol).
  • the total impurity in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is not more than 5% when stored at 25 °C / 60% RH for at least one month, as measured by HPLC method.
  • the active ingredients used in the stable composition comprises of 5- Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof.
  • the concentration of individual active ingredients or its pharmaceutically acceptable salt is from 0.001 to 20% w/w of the total composition.
  • the concentration of 5-Fluorouracil is from 1 to 10% w/w with respect to the total weight of the composition
  • the concentration of Calcipotriol is from 0.001 to 0.01% w/w with respect to the total weight of the composition.
  • the concentration of 5- Fluorouracil is 2.5 to 5 % w/w
  • the concentration of Calcipotriol is 0.0025 to 0.0050 % w/w, with respect to the total weight of the composition.
  • the concentration of 5-Fluorouracil is 2.5 % w/w and the concentration of Calcipotriol is 0.0025 % w/w of the total composition. In a preferred embodiment, the concentration of 5-Fluorouracil is 5 % w/w and the concentration of Calcipotriol is 0.0050 % w/w of the total composition. Further, the amount of the active ingredients in the formulation can be varied that is within the scope of a person skilled in the art.
  • the present invention provides a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is more than 7.
  • the pH of the composition is from 7 to 9.
  • the pH of the composition is from 7.2 to 8.8.
  • the pH of the composition is 8.5.
  • the stable composition of the present invention can comprise pharmaceutically acceptable excipients selected from an emollient, an emulsifying agent, an ointment base, chelating agent, preservative, antioxidant, buffering agent, humectant, penetration enhancer and solvent.
  • pharmaceutically acceptable excipients selected from an emollient, an emulsifying agent, an ointment base, chelating agent, preservative, antioxidant, buffering agent, humectant, penetration enhancer and solvent.
  • the emollient can be selected form the group consisting of aluminum monostearate, castor oil, cetostearyl alcohol, cyclomethicone, dimethicone, glycerin, glyceryl monooleate, glyceryl monostearate, isopropyl myri state, isopropyl palmitate, lecithin, mineral oil, lanolin alcohols, myristyl alcohol, petrolatum and sunflower oil.
  • the emollient used in the stable topical cream comprising 5-fluorouracil and calcipotriol is cetostearyl alcohol.
  • the ointment base can be selected form the group consisting of lanolin, liquid paraffin, petrolatum, lanolin alcohols, polyethylene glycol, white petrolatum.
  • the ointment base used in the stable topical cream comprising 5-fluorouracil and calcipotriol is petrolatum and liquid paraffin.
  • the chelating agent can be selected form the group consisting of calcium acetate, hydroxypropyl betadex, potassium citrate, citric acid, citric acid monohydrate, disodium edetate, sodium citrate dihydrate, dibasic sodium phosphate and tartaric acid.
  • the chelating agent used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is disodium edetate (i.e. EDTA).
  • the antioxidant can be selected form the group consisting of dl-alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, citric acid monohydrate, malic acid, methionine, potassium metabi sulfite, propionic acid, propyl gallate, sodium ascorbate, sodium metabi sulfite, sodium sulfite and sodium thiosulfate.
  • the antioxidant used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is dl-alpha tocopherol.
  • the preservative can be selected form the group consisting of benzalkonium chloride, dichlorobenzyl alcohol, benzyl alcohol, boric acid, chlorhexidine, chlorobutanol, cresol, glycerin, hexetidine, potassium benzoate, potassium metabi sulfite, potassium sorbate, propylene glycol, sodium acetate, sodium benzoate and thimerosal.
  • the preservative used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is dichlorobenzyl alcohol.
  • the penetration enhancer can be selected form the group consisting of alcohol, dimethyl sulfoxide, ceteth-20 ® , polyoxyethylene alkyl ethers, docusate sodium, glyceryl monooleate, lauric acid, myristyl alcohol, phospholipids, sodium lauryl sulfate, sorbitan esters (sorbitan fatty acid esters), isopropyl myristate, isopropyl palmitate, lanolin and oleyl alcohol.
  • the penetration enhancer used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is ceteth-20 ® (polyoxyl 20 cetostearyl ether).
  • the emulsifying agent can be selected form the group consisting of hypromellose, sodium lauryl sulfate, sorbitan esters (sorbitan fatty acid esters), carboxymethylcellulose sodium, Polyoxyethylene Sorbitan Fatty Acid, Cetostearyl alcohol and Ceteth-20 ® (polyoxyl 20 cetostearyl ether).
  • the emulsifying agent used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is Cetostearyl alcohol.
  • the buffering agent can be selected form the group consisting of disodium hydrogen phosphate dihydrate, malic acid, sodium borate, sodium citrate dihydrate, sodium borate and sodium hydroxide.
  • the buffering agents used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol are disodium hydrogen phosphate dihydrate and sodium hydroxide.
  • the humectant can be selected form the group consisting of glycerin, polydextrose, propylene glycol, sodium lactate, sorbitol, triacetin, trehalose and xylitol.
  • the humectant used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is glycerin.
  • the solvent can be selected form the group consisting of purified water, alcohols, isopropyl alcohol, polyethylene glycol and propylene glycol.
  • the solvent used in the stable topical cream comprising 5- Fluorouracil and Calcipotriol is purified water.
  • the present invention relates to a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and the following pharmaceutically acceptable excipients: cetostearyl alcohol, petrolatum, liquid paraffin, dichlorobenzyl alcohol, dl-a tocopherol, Ceteth-20 ® (polyoxyl 20 cetostearyl ether), di sodium hydrogen phosphate dihydrate, disodium edetate, glycerin, and sodium hydroxide and water.
  • cetostearyl alcohol petrolatum, liquid paraffin, dichlorobenzyl alcohol, dl-a tocopherol, Ceteth-20 ® (polyoxyl 20 cetostearyl ether), di sodium hydrogen phosphate dihydrate, disodium edetate, glycerin, and sodium hydroxide and water.
  • the stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, can be prepared by a process that involves mixing the components of the water phase and the wax phase until a cream-like consistency is obtained.
  • the water phase preparation involves the addition of the active ingredients with the pharmaceutically acceptable excipients that are fairly soluble or completely soluble in water such that a clear solution is obtained.
  • the wax phase preparation involves the addition of the pharmaceutically acceptable excipients that are poorly soluble or insoluble in water. Both the wax phase and the water phase are homogenously mixed with stirring, until a cream-like consistency is achieved for the final composition.
  • the obtained topical composition is filled into suitable packaging container such as aluminum collapsible tubes.
  • the present invention provides a process for the preparation of a stable composition; wherein the process comprises the steps of:
  • Cream preparation
  • the present invention provides a process for the preparation of a stable composition; wherein the process comprises the steps of:
  • Cream preparation 1. Transfer the hot wax phase maintained at 55°C-60°C in water phase maintained at 25°C-30°C. Homogenize with stirring maintaining the temperature at 25°C-35°C till cream-like consistency is achieved.
  • the assay of 5-Fluorouracil and Calcipotriol in the topical cream composition according to the present invention can be carried out by any of the methods known to a person skilled in the art.
  • the assay can be performed by HPLC method.
  • Example-1 Stable topical pharmaceutical composition
  • the composition of the Example- 1 can be prepared by a process that involves mixing the components of the water phase and the wax phase until a cream-like consistency is obtained. The detailed steps of the manufacturing process are mentioned in the detailed description.
  • Example-2 Stable topical pharmaceutical compositions
  • composition can be obtained by a manufacturing process comprising the following steps:
  • Wax Phase preparation 1. Transfer weighed quantity of liquid paraffin/mineral oil, dl-a tocopherol, cetostearyl alcohol, dichlorobenzyl alcohol and petrolatum with stirring.
  • Example-3 Stability data for pharmaceutical composition of Formula-1
  • Example-5 Stability data for pharmaceutical composition of Formula-3
  • Example-6 Stability data for pharmaceutical composition of Formula-4
  • Example-8 Stability data for pharmaceutical composition of Formula-6
  • the data confirms that the individual assay of 5-Fluorouracil and Calcipotriol in all the compositions is above 95% when stored at 2°C - 8°C and total impurity of 5-Fluorouracil and Calcipotriol is in control for 6 months.
  • Example-10 Stability data for pharmaceutical composition of Formula-1-6 (25°C, 60% RH for 6 months)
  • the Formula-5 was selected for further studies, as this composition remained stable when stored at 25°C / 60% RH for at least six months.
  • the data shows that individual assay of 5-Fluorouracil and Calcipotriol is above 95%, and the total impurity of 5 -Fluorouracil and Calcipotriol is not more than 5% when stored at 25°C / 60% RH for at least six months.
  • Formulation at pH 8.5 is stable at 25°C and is also having better impurity profile at 40°C as compared to formulation with pH 8.2.
  • the results indicate that the pH from 7 to 9 is useful to stabilize Calcipotriol in the presence of 5 -Fluorouracil. Further, the pharmaceutical composition remains stable, when stored at 25 °C / 60% RH for at least three months.
  • Example-11 Stable topical pharmaceutical composition comprising higher strength of Fluorouracil and Calcipotriol (pH 8.5 with chelating agent)
  • Example-12 Stability results of Formula-7 with higher strength of
  • the individual assay of 5-Fluorouracil and Calcipotriol in the higher strength composition is at least 95%, and the total impurity in the said composition is not more than 5%, when stored at 25 °C / 60% RH for at least one month, preferably for at least three months.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, for use in the treatment of actinic keratosis and other skin diseases. Further, the present invention provides a process for the preparation of the said composition.

Description

STABLE TOPICAL PHARMACEUTICAL COMPOSITION RELATED APPLICATIONS
This application is related to Indian Provisional Application No. IN201921047008 filed on 19th November, 2019 and is incorporated herein in its entirety.
FIELD OF THE INVENTION
The present invention provides a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, for use in the treatment of actinic keratosis and other skin diseases. Further, the present invention provides a process for the preparation of the said composition. BACKGROUND OF THE INVENTION
5-Fluorouracil is thymidylate synthase (TS) inhibitor, which is chemically 5- Fluoro-IH, 3H-pyrimidine-2,4-dione. The empirical formula of 5-Fluorouracil is C4H3FN2O2 and it has the structural formula (I).
Figure imgf000002_0001
5-Fluorouracil (5-FU) is sold under the brand name as Adrucil® Injection and Efudex® Cream. By injection into a vein, it is used for colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer. As a cream, it is used for actinic keratosis, basal cell carcinoma, and skin warts. Efudex® Cream is stored at 25° C; excursions permitted to 15°C to 30°C.
Calcipotriol, also known as calcipotriene, is a synthetic derivative of calcitriol, a form of vitamin D, which is chemically (lR,3S,5E)-5-{ 2-[(lR,3aS,4Z,7aR)-l- [(2R,3E)5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7amethyl-octahydro-lH-inden- 4-ylidene]ethylidene}-4-methylidenecyclohyytyexane-l,3-diol. The empirical formula of Calcipotriol is C27H40O3 and it has the structural formula (II).
Figure imgf000003_0001
Calcipotriol is sold under the trade name Dovonex® in the United States, Daivonex® outside North America, and Psorcutan® in Germany. It is used in the treatment of psoriasis. It is safe for long-term application in psoriatic skin conditions. Dovonex® is stored at controlled room temperature 15° C to 25° C.
The US Patent No. US7169401 discloses a skin hydrating cream base consisting essentially of a hypoallergenic peanut oil, and an active ingredient, wherein said the active ingredient is fluorouracil.
The US Patent No. US6670335 discloses an oil-in-water emulsion formulation containing fluorouracil suitable for topical administration, and is useful for the treatment of solar keratosis, actinic keratosis, and superficial basal cell carcinoma. The PCT Patent application No. WO2016040638 discloses compositions and methods for the treatment of precancerous skin lesions. The compositions of the invention comprise 5-fluorouracil (5-FU) and a vitamin D analog. The combined use of 5-FU and calcipotriol results in significantly higher clearance of actinic keratosis as compared to standard of care treatment (5-FU+Vaseline). However, there is no guidance on how to prepare a stable composition comprising 5-FU and calcipotriol. Further, the patent specification does not provide any reference related to a stable composition comprising 5-FU and calcipotriol.
The combination therapy has proved to be a preferred solution to improve patient’s adherence when a treatment requires the co-administration of drugs. Additionally, the combination therapy can reduce the costs of production and distribution of the treatment. However, in many cases, the design of a combination proves difficult for the reason such as chemical incompatibility between the different active ingredients or difficulties for co-formulating active ingredients to be administered with different release.
Although 5-FU and calcipotriol are available as cream compositions, when the combination is prepared by mixing the individual drug compositions, the assay of calcipotriol gets reduced, and therefore a stable combination product cannot be obtained by physical mixing of the individual drugs. Hence, there exists a need for a stable fixed-dose combination product containing such active ingredients which may not give rise to degradation of the active ingredients. The inventors of the present invention have developed a new stable fixed-dose topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, for use in the treatment of actinic keratosis and other skin diseases. OBJECT OF THE INVENTION The main object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof.
Another object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream, an ointment, or a lotion.
Another object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is more than 7.
Another object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is from 7 to 9.
Another object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is from 7 to 9 and further comprising a chelating agent.
Another object of the present invention is to provide a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient selected from an emollient, an emulsifying agent, an ointment base, a chelating agent, a preservative, an antioxidant, a buffering agent, a humectant, a penetration enhancer and a solvent. Another object of the present invention is to provide a process for preparation of stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream, an ointment, or a lotion.
Another object of the present invention is to provide a process for preparation of stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream prepared by mixing the components of the water phase and the wax phase.
Another object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the individual assay of 5- Fluorouracil and Calcipotriol in the said composition is at least 95% when stored at 25 °C / 60% RH for at least one month.
Another object of the present invention is to provide a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the total impurity in the said composition is not more than 5% when stored at 25 °C / 60% RH for at least one month.
Another object of the present invention refers to an aluminum collapsible tube packaging container comprising a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof.
Another object of the present invention is to provide a stable topical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, for human administration for the treatment of actinic keratosis, precancerous skin lesions and other skin diseases.
SUMMARY OF THE INVENTION
In a first embodiment, the present invention relates to a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof.
In another embodiment, the present invention relates to a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream, an ointment, or a lotion.
In another embodiment, the present invention relates to a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof with at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is more than 7.
In another embodiment, the present invention relates to a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is from 7 to 9.
In another embodiment, the present invention relates to a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is from 7 to 9 and further comprising a chelating agent. In another embodiment, the present invention relates to a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients selected from an emollient, an emulsifying agent, an ointment base, chelating agent, preservative, antioxidant, buffering agent, humectant, penetration enhancer and solvent.
In another embodiment, the present invention relates to a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and the following pharmaceutically acceptable excipients: cetostearyl alcohol, petrolatum, liquid paraffin, dichlorobenzyl alcohol, dl-a tocopherol, ceteth-20®, disodium hydrogen phosphate dihydrate, disodium edetate, glycerin, and sodium hydroxide and purified water.
In another embodiment, the present invention relates to a process for preparation of stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream prepared by mixing the components of the water phase and the wax phase.
In another embodiment, the present invention relates to a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the individual assay of 5- Fluorouracil and Calcipotriol in the said composition is at least 95% when stored at 25 °C / 60% RH for at least one month.
In another embodiment, the present invention relates to a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the total impurity in the said composition is not more than 5% when stored at 25 °C / 60% RH for at least one month. In another embodiment, the present invention relates to a stable topical composition comprising 2.5% w/w of 5-Fluorouracil and 0.0025% w/w of Calcipotriol or pharmaceutically acceptable salts thereof, wherein the pH of the said composition is from 7 to 9, and total impurity in the said composition is not more than 5% when stored at 25 °C / 60% RH for at least one month.
In another embodiment, the present invention relates to a stable topical composition comprising 5% w/w of 5-Fluorouracil and 0.0050% w/w of Calcipotriol or pharmaceutically acceptable salts thereof, wherein the pH of the said composition is from 7 to 9, and total impurity in the said composition is not more than 5% when stored at 25 °C / 60% RH for at least one month.
In another embodiment, the present invention relates to a stable topical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition can be used for human administration for the treatment of actinic keratosis, precancerous skin lesions and other skin diseases.
DETAILED DESCRIPTION OF THE INVENTION
The detailed description and the examples provided herein are exemplary and any modification or variation within the scope of the invention will be apparent to a person skilled in the art. Further, unless otherwise defined, all the technical and scientific terms used herein shall bear the meaning as understood by a person who is ordinarily skilled in the art. Any ranges given herein include both the lower and the upper endpoints of the range. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.
In one embodiment, the present invention provides a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the said composition is a cream, an ointment, or a lotion.
The term “stable pharmaceutical composition” of the present invention means the topical composition retains consistency as a white opaque cream and the individual assay of 5-Fluorouracil and Calcipotriol in the said composition is at least 95% when stored at 25 °C / 60% RH for at least one month, preferably for at least 2 months, and more preferably for at least 3 months. The abbreviation “RH” stands for relative humidity corresponding to the storage conditions. The individual assay of the active ingredient can be carried out by any conventional analytical methods, preferably by HPLC method. The HPLC (High-performance liquid chromatography) technique in analytical chemistry is used to separate, identify, and quantify each component in a mixture. The HPLC method is well known in the art for the quantification and qualification of analytes.
The impurities for Calcipotriol are characterized as follows:
Impurity B: (5Z,7Z,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22- tetraene- 1 a,3b,244cΐo1 ((7Z)-calcipotriol),
Impurity C: (5E,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22- tetraene- 1 a,3b,244cΐo1 ((5E)-calcipotriol),
Impurity D: (5Z,7E,22E,24R)-24-cyclopropyl-9,10-secochola-5,7,10(19),22- tetraene- 1 a,3b,244cΐo1 (24-epi-calcipotriol).
In a preferred embodiment, the total impurity in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is not more than 5% when stored at 25 °C / 60% RH for at least one month, as measured by HPLC method.
The active ingredients used in the stable composition comprises of 5- Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof. In a preferred embodiment, the concentration of individual active ingredients or its pharmaceutically acceptable salt is from 0.001 to 20% w/w of the total composition. In one embodiment, the concentration of 5-Fluorouracil is from 1 to 10% w/w with respect to the total weight of the composition, and the concentration of Calcipotriol is from 0.001 to 0.01% w/w with respect to the total weight of the composition. In a preferred embodiment, the concentration of 5- Fluorouracil is 2.5 to 5 % w/w, and the concentration of Calcipotriol is 0.0025 to 0.0050 % w/w, with respect to the total weight of the composition.
In a preferred embodiment, the concentration of 5-Fluorouracil is 2.5 % w/w and the concentration of Calcipotriol is 0.0025 % w/w of the total composition. In a preferred embodiment, the concentration of 5-Fluorouracil is 5 % w/w and the concentration of Calcipotriol is 0.0050 % w/w of the total composition. Further, the amount of the active ingredients in the formulation can be varied that is within the scope of a person skilled in the art.
In another embodiment, the present invention provides a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is more than 7. In a preferred embodiment, the pH of the composition is from 7 to 9. In another preferred embodiment, the pH of the composition is from 7.2 to 8.8. In a more preferred embodiment, the pH of the composition is 8.5.
The stable composition of the present invention can comprise pharmaceutically acceptable excipients selected from an emollient, an emulsifying agent, an ointment base, chelating agent, preservative, antioxidant, buffering agent, humectant, penetration enhancer and solvent.
The emollient can be selected form the group consisting of aluminum monostearate, castor oil, cetostearyl alcohol, cyclomethicone, dimethicone, glycerin, glyceryl monooleate, glyceryl monostearate, isopropyl myri state, isopropyl palmitate, lecithin, mineral oil, lanolin alcohols, myristyl alcohol, petrolatum and sunflower oil. In a preferred embodiment, the emollient used in the stable topical cream comprising 5-fluorouracil and calcipotriol is cetostearyl alcohol.
The ointment base can be selected form the group consisting of lanolin, liquid paraffin, petrolatum, lanolin alcohols, polyethylene glycol, white petrolatum. In a preferred embodiment, the ointment base used in the stable topical cream comprising 5-fluorouracil and calcipotriol is petrolatum and liquid paraffin.
The chelating agent can be selected form the group consisting of calcium acetate, hydroxypropyl betadex, potassium citrate, citric acid, citric acid monohydrate, disodium edetate, sodium citrate dihydrate, dibasic sodium phosphate and tartaric acid. In a preferred embodiment, the chelating agent used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is disodium edetate (i.e. EDTA).
The antioxidant can be selected form the group consisting of dl-alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, citric acid monohydrate, malic acid, methionine, potassium metabi sulfite, propionic acid, propyl gallate, sodium ascorbate, sodium metabi sulfite, sodium sulfite and sodium thiosulfate. In a preferred embodiment, the antioxidant used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is dl-alpha tocopherol.
The preservative can be selected form the group consisting of benzalkonium chloride, dichlorobenzyl alcohol, benzyl alcohol, boric acid, chlorhexidine, chlorobutanol, cresol, glycerin, hexetidine, potassium benzoate, potassium metabi sulfite, potassium sorbate, propylene glycol, sodium acetate, sodium benzoate and thimerosal. In a preferred embodiment, the preservative used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is dichlorobenzyl alcohol. The penetration enhancer can be selected form the group consisting of alcohol, dimethyl sulfoxide, ceteth-20®, polyoxyethylene alkyl ethers, docusate sodium, glyceryl monooleate, lauric acid, myristyl alcohol, phospholipids, sodium lauryl sulfate, sorbitan esters (sorbitan fatty acid esters), isopropyl myristate, isopropyl palmitate, lanolin and oleyl alcohol. In a preferred embodiment, the penetration enhancer used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is ceteth-20® (polyoxyl 20 cetostearyl ether).
The emulsifying agent can be selected form the group consisting of hypromellose, sodium lauryl sulfate, sorbitan esters (sorbitan fatty acid esters), carboxymethylcellulose sodium, Polyoxyethylene Sorbitan Fatty Acid, Cetostearyl alcohol and Ceteth-20® (polyoxyl 20 cetostearyl ether). In a preferred embodiment, the emulsifying agent used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is Cetostearyl alcohol.
The buffering agent can be selected form the group consisting of disodium hydrogen phosphate dihydrate, malic acid, sodium borate, sodium citrate dihydrate, sodium borate and sodium hydroxide. In a preferred embodiment, the buffering agents used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol are disodium hydrogen phosphate dihydrate and sodium hydroxide.
The humectant can be selected form the group consisting of glycerin, polydextrose, propylene glycol, sodium lactate, sorbitol, triacetin, trehalose and xylitol. In a preferred embodiment, the humectant used in the stable topical cream comprising 5-Fluorouracil and Calcipotriol is glycerin.
The solvent can be selected form the group consisting of purified water, alcohols, isopropyl alcohol, polyethylene glycol and propylene glycol. In a preferred embodiment, the solvent used in the stable topical cream comprising 5- Fluorouracil and Calcipotriol is purified water. In a preferred embodiment, the present invention relates to a stable topical cream comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, and the following pharmaceutically acceptable excipients: cetostearyl alcohol, petrolatum, liquid paraffin, dichlorobenzyl alcohol, dl-a tocopherol, Ceteth-20® (polyoxyl 20 cetostearyl ether), di sodium hydrogen phosphate dihydrate, disodium edetate, glycerin, and sodium hydroxide and water.
In another embodiment, the stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, can be prepared by a process that involves mixing the components of the water phase and the wax phase until a cream-like consistency is obtained.
The water phase preparation involves the addition of the active ingredients with the pharmaceutically acceptable excipients that are fairly soluble or completely soluble in water such that a clear solution is obtained. Further, the wax phase preparation involves the addition of the pharmaceutically acceptable excipients that are poorly soluble or insoluble in water. Both the wax phase and the water phase are homogenously mixed with stirring, until a cream-like consistency is achieved for the final composition. The obtained topical composition is filled into suitable packaging container such as aluminum collapsible tubes.
In another embodiment, the present invention provides a process for the preparation of a stable composition; wherein the process comprises the steps of:
Water Phase preparation:
1. Transfer required quantity of purified water in a vessel and heat the purified water between 60-65 °C with continuous stirring.
2. Add buffering agent and penetration enhancer into water.
3. Add Calcipotriol, chelating agent and humectant to form a clear solution.
4. Add 5-Fluorouracil and adjust the pH more than 7.0 using NaOH solution. Wax Phase preparation:
1. Transfer weighed quantity of emollient, antioxidant, emulsifying agent, preservative and ointment base in a vessel.
2. Heat to 70°C-80°C and stir till melt followed by gradual cooling.
Cream preparation:
1. Transfer the hot wax phase maintained at 55°C-60°C in water phase maintained at 25°C-30°C. Homogenize with stirring maintaining the temperature at 25°C-35°C till cream-like consistency is achieved.
2. Fill the cream into suitable packaging container such as aluminum collapsible tubes.
In a preferred embodiment, the present invention provides a process for the preparation of a stable composition; wherein the process comprises the steps of:
Water Phase preparation:
1. Transfer required quantity of purified water in a vessel and heat the purified water between 60-65 °C with continuous stirring.
2. Add Disodium hydrogen phosphate dihydrate and Ceteth-20® into water.
3. Add Calcipotriol, Edetate Disodium and Glycerin to form a clear solution.
4. Add 5-Fluorouracil and adjust the pH more than 7.0 using NaOH solution.
Wax Phase preparation:
1. Transfer weighed quantity of Liquid Paraffm/Mineral oil, dl-a tocopherol, Cetostearyl alcohol, Dichlorobenzyl alcohol and Petrolatum with stirring.
2. Heat to 70°C-80°C and stir till melt followed by gradual cooling.
Cream preparation: 1. Transfer the hot wax phase maintained at 55°C-60°C in water phase maintained at 25°C-30°C. Homogenize with stirring maintaining the temperature at 25°C-35°C till cream-like consistency is achieved.
2. Fill the cream into suitable packaging container such as aluminum collapsible tubes.
The assay of 5-Fluorouracil and Calcipotriol in the topical cream composition according to the present invention can be carried out by any of the methods known to a person skilled in the art. In a preferred embodiment, the assay can be performed by HPLC method.
Examples
The present invention has been described by way of example only, and it is to be recognized that modifications thereto falling within the scope and spirit of the appended claims, and which would be obvious to a person skilled in the art based upon the disclosure herein, are also considered to be included within the scope of this invention. Example-1: Stable topical pharmaceutical composition
Figure imgf000016_0001
The composition of the Example- 1 can be prepared by a process that involves mixing the components of the water phase and the wax phase until a cream-like consistency is obtained. The detailed steps of the manufacturing process are mentioned in the detailed description.
Example-2: Stable topical pharmaceutical compositions
Figure imgf000017_0001
The composition can be obtained by a manufacturing process comprising the following steps:
Water Phase preparation:
1. Transfer required quantity of purified water in a vessel and heat the purified water between 60-65 °C with continuous stirring.
2. Add disodium hydrogen phosphate dihydrate and ceteth-20® into water. 3. Add calcipotriol, edetate disodium and glycerin to form a clear solution.
4. Add 5-Fluorouracil and adjust the pH more than 7.0 using NaOH solution.
Wax Phase preparation: 1. Transfer weighed quantity of liquid paraffin/mineral oil, dl-a tocopherol, cetostearyl alcohol, dichlorobenzyl alcohol and petrolatum with stirring.
2. Heat to 70°C-80°C and stir till melt followed by gradual cooling. Cream preparation:
1. Transfer the hot wax phase maintained at 55°C-60°C in water phase maintained at 25°C-30°C. Homogenize with stirring maintaining the temperature at 25°C-35°C till cream-like consistency is achieved.
2. Fill the cream into suitable packaging container such as aluminum collapsible tubes.
Example-3: Stability data for pharmaceutical composition of Formula-1
Figure imgf000018_0001
ND = Not detected The data shows that the assay of 5-Fluorouracil and Calcipotriol is above 95%, when stored at 25 °C / 60% RH for composition at pH 7.2 with chelating agent (EDTA). Example-4: Stability data for pharmaceutical composition of Formula-2
Figure imgf000019_0001
The results exhibit that the presence of chelating agent (EDTA) in the composition marginally helps in stabilizing Calcipotriol in the composition having pH 7.2.
Example-5: Stability data for pharmaceutical composition of Formula-3
Figure imgf000019_0002
Figure imgf000020_0001
The results exhibit the favorable impact of pH 8.2 as compared to pH 7.2 for stabilization of Calcipotriol in the cream composition. Example-6: Stability data for pharmaceutical composition of Formula-4
Figure imgf000020_0002
The data shows that in absence of chelating agent (EDTA) at pH 8.2, the assay of Calcipotriol slightly decreases at 25°C and 40°C. Example-7: Stability data for pharmaceutical composition of Formula-5
Figure imgf000021_0001
At pH 8.5 with chelating agent (EDTA), assay of both 5-Fluorouracil and Calcipotriol is stable even at accelerated stability condition (40°C / 75% RH). The impurity profile of both 5-Fluorouracil and Calcipotriol is found to be better as compared to pH 8.2.
Example-8: Stability data for pharmaceutical composition of Formula-6
Figure imgf000021_0002
Figure imgf000022_0001
The presence of chelating agent (EDTA) shows positive impact on stabilization of both 5-Fluorouracil and Calcipotriol at pH 8.5. Example-9: Stability data for pharmaceutical composition of Formula-1-6 (2°C - 8°C for 6 months)
Figure imgf000022_0002
Figure imgf000023_0001
ND: Not Detected
The data confirms that the individual assay of 5-Fluorouracil and Calcipotriol in all the compositions is above 95% when stored at 2°C - 8°C and total impurity of 5-Fluorouracil and Calcipotriol is in control for 6 months.
Example-10: Stability data for pharmaceutical composition of Formula-1-6 (25°C, 60% RH for 6 months)
Figure imgf000023_0002
ND: Not Detected
Based on the stability results, the Formula-5 was selected for further studies, as this composition remained stable when stored at 25°C / 60% RH for at least six months. The data shows that individual assay of 5-Fluorouracil and Calcipotriol is above 95%, and the total impurity of 5 -Fluorouracil and Calcipotriol is not more than 5% when stored at 25°C / 60% RH for at least six months.
Several experiments were performed by the inventors to assess the impact of pH on stabilization of the cream. The results indicated that the pH 8.2 had a favorable impact on cream stability compared to pH 7.2. Further, the presence of chelating agent (EDTA) in the composition showed positive impact on stabilization of both Fluorouracil and Calcipotriol compared to the compositions without chelating agent (EDTA). Fluorouracil and Calcipotriol cream formulated with or without chelating agent (EDTA) at pH 8.5 has even better stabilization of Calcipotriol as compared to formulation with pH 8.2. Presence of chelating agent (EDTA) helps in stabilization of formulation at this pH. Formulation at pH 8.5 is stable at 25°C and is also having better impurity profile at 40°C as compared to formulation with pH 8.2. The results indicate that the pH from 7 to 9 is useful to stabilize Calcipotriol in the presence of 5 -Fluorouracil. Further, the pharmaceutical composition remains stable, when stored at 25 °C / 60% RH for at least three months.
Above data indicates that pH plays crucial role in stabilization of Calcipotriol in the presence of Fluorouracil. The Formula-5 was found to be most stable formulation amongst all the formulations studied.
Based on the above batches, it was observed that both Fluorouracil and Calcipotriol were found to be stable even at 25 °C / 60% RH in terms of content and impurities at pH 8.5 in the presence of chelating agent (EDTA). Therefore, a batch was prepared with higher concentration of both Fluorouracil and Calcipotriol at pH 8.5 in the presence of chelating agent (EDTA).
Example-11: Stable topical pharmaceutical composition comprising higher strength of Fluorouracil and Calcipotriol (pH 8.5 with chelating agent)
Figure imgf000024_0001
Figure imgf000025_0001
The composition of the above Example can be prepared by the process as described in the Example-2. Example-12: Stability results of Formula-7 with higher strength of
Fluorouracil and Calcipotriol (pH 8.5 with chelating agent)
Figure imgf000025_0002
Figure imgf000026_0001
At pH 8.5 with EDTA, the individual assay of 5-Fluorouracil and Calcipotriol in the higher strength composition is at least 95%, and the total impurity in the said composition is not more than 5%, when stored at 25 °C / 60% RH for at least one month, preferably for at least three months.

Claims

We claim:
1. A stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof with at least one pharmaceutically acceptable excipient, wherein the pH of the said composition is more than 7.
2. The stable topical pharmaceutical composition according to claim 1, wherein the said composition is a cream, an ointment, or a lotion.
3. The stable topical pharmaceutical composition according to claim 1, wherein the concentration of 5-Fluorouracil is 2.5 to 5 % w/w, and the concentration of Calcipotriol is 0.0025 to 0.0050 % w/w % w/w with respect to the total weight of the composition.
4. The stable topical pharmaceutical composition according to claim 1, wherein the concentration of 5-Fluorouracil is 2.5 % w/w and the concentration of Calcipotriol is 0.0025 % w/w, with respect to the total weight of the composition.
5. The stable topical pharmaceutical composition according to claim 1, wherein the concentration of 5-Fluorouracil is 5 % w/w and the concentration of Calcipotriol is 0.0050 % w/w, with respect to the total weight of the composition.
6. The stable topical pharmaceutical composition according to claim 1, wherein the pH of the said composition is from 7 to 9, and further comprising a chelating agent.
7. The stable topical pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable excipients include cetostearyl alcohol, petrolatum, liquid paraffin, dichlorobenzyl alcohol, dl-a tocopherol, ceteth- 20®, di sodium hydrogen phosphate dihydrate, di sodium edetate, glycerin, and sodium hydroxide, and purified water.
8. The stable topical pharmaceutical composition according to claim 1, wherein the individual assay of 5-Fluorouracil and Calcipotriol in the said composition is at least 95% when stored at 25°C / 60% RH for at least one month.
9. The stable topical pharmaceutical composition according to claim 1, wherein the total impurity in the said composition is not more than 5% when stored at 25°C / 60% RH for at least one month.
10. A stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the pH of the said composition is from 7 to 9, and wherein the individual assay of 5- Fluorouracil and Calcipotriol is at least 95%, and the total impurity in the said composition is not more than 5% when stored at 25°C / 60% RH for at least one month.
11. A process for preparation of stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, wherein the pH of the said composition is more than 7, comprising the following steps:
(a) Preparation of water phase:
(i) Transfer required quantity of purified water in a vessel and heat the purified water between 60-65 °C with continuous stirring. (ii) Add buffering agent and penetration enhancer into water.
(iii) Add Calcipotriol, chelating agent and humectant to form a clear solution.
(iv) Add 5-Fluorouracil and adjust the pH more than 7.0 using NaOH solution.
(b) Wax Phase preparation: (i) Transfer weighed quantity of emollient, antioxidant, emulsifying agent, preservative and ointment base with stirring in a vessel.
(ii) Heat to 70°C-80°C and stir till melt followed by gradual cooling.
(c) Cream preparation: (i) Transfer the hot wax phase maintained at 55°C-60°C in water phase maintained at 25°C-30°C. Homogenize with stirring maintaining the temperature at 25°C-35°C till cream-like consistency is achieved.
(ii) Fill the cream into suitable packaging container such as aluminum collapsible tubes.
12. The stable topical pharmaceutical composition according to claim 1, wherein the said composition can be used for human administration for the treatment of actinic keratosis, precancerous skin lesions and other skin diseases.
PCT/IB2020/060687 2019-11-19 2020-11-13 Stable topical pharmaceutical composition WO2021099901A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921047008 2019-11-19
IN201921047008 2019-11-19

Publications (1)

Publication Number Publication Date
WO2021099901A1 true WO2021099901A1 (en) 2021-05-27

Family

ID=75980434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/060687 WO2021099901A1 (en) 2019-11-19 2020-11-13 Stable topical pharmaceutical composition

Country Status (1)

Country Link
WO (1) WO2021099901A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143986A1 (en) * 2009-06-10 2010-12-16 Instytut Farmaceutyczny Combined therapy of colorectal carcinoma
WO2016040638A2 (en) * 2014-09-10 2016-03-17 Washington University Compositions and methods for treatment of pre-cancerous skin lesions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143986A1 (en) * 2009-06-10 2010-12-16 Instytut Farmaceutyczny Combined therapy of colorectal carcinoma
WO2016040638A2 (en) * 2014-09-10 2016-03-17 Washington University Compositions and methods for treatment of pre-cancerous skin lesions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CUNNINGHAM TREVOR J., TABACCHI MARY, ELIANE JEAN-PIERRE, TUCHAYI SARA MORADI, MANIVASAGAM SINDHU, MIRZAALIAN HENGAMEH, TURKOZ AHU,: "Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy", J. CLIN. INVEST., vol. 127, no. 1, 3 January 2017 (2017-01-03), pages 106 - 116, XP055826102, Retrieved from the Internet <URL:https://pubmed.ncbi.nlm.nih.gov/27869649/page106> *

Similar Documents

Publication Publication Date Title
JP4311369B2 (en) Stable pharmaceutical composition containing 4,5-epoxymorphinan derivative
JP5688405B2 (en) Antifungal pharmaceutical composition
CN113975280B (en) Pharmaceutical composition containing tofacitinib pharmaceutically acceptable salt, preparation and application
US20150238606A1 (en) Pharmaceutical composition containing luliconazole
TWI654981B (en) Medicinal composition comprising dutasteride and propylene glycol monolaurate and preparation method thereof
EP0184942A2 (en) Improved pharmaceutical composition containing 13-CIS vitamin a acid as the active ingredient
JP2008542260A (en) Novel injectable composition and method for its preparation
IE51637B1 (en) Pharmaceutical preparation
US20240252426A1 (en) Improved and stable apremilast pharmaceutical compositions
JPH09501150A (en) Capsule formulation
US10512654B2 (en) Pharmaceutical composition including dutasteride and capsule formulation comprising the same
US11395827B2 (en) Oil-in-water emulsion of mometasone and propylene glycol
TWI552772B (en) Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
US20210059967A1 (en) Liquid parenteral compositions of levothyroxine
EP0416804B1 (en) External preparation containing amusulosin
CA3032453A1 (en) Pharmaceutical formulations and their use
WO2021099901A1 (en) Stable topical pharmaceutical composition
WO2004030665A1 (en) Transparent gel composition, for the administration of diclofenac sodium through the skin
CN113730335B (en) Tofacitinib external pharmaceutical composition and application thereof
US20220331238A1 (en) Oil-in-water emulsion of mometasone
US20230398111A1 (en) Oral formulations of nintedanib and method of manufacturing thereof
JP7350985B2 (en) Composition containing betamethasone valerate
EP4193989A1 (en) A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity
EP4114358A1 (en) Topical pharmaceutical formulations of a cyclic depsipeptide
JP2001122767A (en) Medicinal composition for percutaneous administration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20891177

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20891177

Country of ref document: EP

Kind code of ref document: A1